报价延迟最少15分钟:2026/05/13 16:07 EDT
盘后时段
|
||||
|
1.1778 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.2
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.35/-2.36
|
|
企业价值
5.15M
|
| 资产负债 |
|
每股账面净值
1.03
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY. |
